Q-omics provides the consensus-scored PDE7B profile across patient tissues and cancer cell-line models. PDE7B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PDE7B is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, PDE7B RNA expression shows 19,158 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, COAD, and KIRP as cancer lineages where PDE7B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE7B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE7B survival associations across molecular data types. PDE7B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE7B RNA expression–survival associations across cancer types. High PDE7B expression shows unfavorable associations in ACC, OV, LGG and LAML, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PDE7B RNA expression.
This table summarizes PDE7B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PDE7B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE7B shows lower tumor expression in COAD, KICH, KIRC, KIRP, LUAD and BLCA. The COAD box plot shows higher PDE7B RNA expression in normal versus tumor tissue (log2 FC = −1.418, t-test p < 0.001).
This table shows molecular features associated with PDE7B in patient tissues and cancer cell lines. In patient samples, PDE7B shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, PDE7B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SOFT_TISSUE.
